share_log

Cantor Fitzgerald Initiates Coverage On Verve Therapeutics With Neutral Rating, Announces Price Target of $21

Cantor Fitzgerald Initiates Coverage On Verve Therapeutics With Neutral Rating, Announces Price Target of $21

坎托·菲茨杰拉德以中性評級啟動神韻治療的覆蓋範圍,宣布目標價格為 21 美元
Benzinga Real-time News ·  2023/02/01 07:57

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Neutral rating and announces Price Target of $21.

Cantor Fitzgerald分析師Rick Bienkowski以中性評級啟動對Verve治療公司(納斯達克:VERV)的報道,並宣佈目標價為21美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論